Online inquiry

IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10982MR)

This product GTTS-WQ10982MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10982MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3156MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AR-101
GTTS-WQ13923MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN2477
GTTS-WQ9627MR IVTScrip™ mRNA-Anti-PDCD1, JNJ-63723283(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-63723283
GTTS-WQ14029MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aLAG367
GTTS-WQ12704MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ6270MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CR-6261
GTTS-WQ9909MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA KB-003
GTTS-WQ4359MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW